QTRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Quanterix Corp (QTRX) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown improvement in revenue and net income, the pre-market price decline, lack of strong technical signals, and absence of recent congress trading data or significant positive catalysts suggest holding off on immediate investment. Waiting for the upcoming earnings report or further clarity on financial performance may be prudent.
The MACD histogram is positive at 0.0781 and expanding, indicating bullish momentum. However, the RSI is neutral at 77.559, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot point of 6.086, with resistance at 6.579 and support at 5.593. Overall, the technical indicators are mixed and do not provide a strong buy signal.
Revenue increased by 12.34% YoY in Q3
Net income improved significantly, up 301.26% YoY.
Acquisition of Akoya Biosciences enhances capabilities in precision medicine and biomarker detection.
Upcoming Q4 2025 earnings report on March 2, 2026, could provide further insights.
Gross margin dropped by 23.99% YoY, indicating potential cost pressures.
Pre-market price decline of -0.30%.
Lack of significant hedge fund or insider trading activity.
No recent congress trading data or strong technical signals.
In Q3 2025, revenue increased by 12.34% YoY to $40.23M, and net income improved significantly, up 301.26% YoY to -$33.52M. EPS also improved by 231.82% YoY to -0.73. However, gross margin dropped to 42.77%, down 23.99% YoY, which raises concerns about cost efficiency.
Canaccord recently raised the price target from $5 to $8 while maintaining a Hold rating. The firm believes the life science tools and diagnostics sector has momentum, which could continue into 2026.
